Hostname: page-component-74656f9884-8r8nv Total loading time: 0 Render date: 2026-11-08T09:36:49.214Z Has data issue: false hasContentIssue false

Down syndrome: otolaryngological effects of rapid maxillary expansion

Published online by Cambridge University Press:  25 June 2008

C Pinto de Moura*
Affiliation:
Department of Otolaryngology, Hospital São João, University of Porto Medical School, Portugal Department of Medical Genetics, Hospital São João, University of Porto Medical School, Portugal
D Andrade
Affiliation:
Paediatric Dentistry Department, University of Porto Dental Medical School, Portugal
L M Cunha
Affiliation:
REQUIMTE, Faculty of Sciences, University of Porto, Portugal
M J Tavares
Affiliation:
Paediatric Dentistry Department, University of Porto Dental Medical School, Portugal
M J Cunha
Affiliation:
Department of Speech Therapy, University of Porto Superior Health Technology School, Portugal
P Vaz
Affiliation:
Paediatric Dentistry Department, University of Porto Dental Medical School, Portugal
H Barros
Affiliation:
Department of Epidemiology, Hospital São João, University of Porto Medical School, Portugal
S M Pueschel
Affiliation:
Department of Paediatrics, Brown University, School of Medicine, Providence, Rhode Island, USA
M Pais Clemente
Affiliation:
Department of Otolaryngology, Hospital São João, University of Porto Medical School, Portugal
*
Address for correspondence: Dr Carla Pinto de Moura, Department of Otolaryngology, Hospital São João, Porto Medical School, Alameda Hernani Monteiro, 4200-251 Porto, Portugal. E-mail: cmoura@med.up.pt
Rights & Permissions [Opens in a new window]

Abstract

Objective:

Phenotypical Down syndrome includes pharyngeal and maxillary hypoplasia and, frequently, constricted maxillary arch with nasal obstruction.

Study design:

This clinical trial assessed the effects of rapid maxillary expansion on ENT disorders in 24 children with Down syndrome randomly allocated to receive either rapid maxillary expansion or not. Each group received ENT and speech therapy assessments before expansion and after the device had been removed.

Results:

In the rapid maxillary expansion group, the yearly ENT infection rate was reduced when assessed after device removal (p < 0.01). The parents of rapid maxillary expansion children reported a reduction in respiratory obstruction symptoms. Audiological assessment revealed improvements in the rapid maxillary expansion group (p < 0.01). Cephalometry showed increased maxillary width in the rapid maxillary expansion group.

Conclusions:

Rapid maxillary expansion resulted in a reduction in hearing loss, yearly rate of ENT infections and parentally assessed symptoms of upper airway obstruction, compared with no treatment. These findings are probably related to expanded oronasal space, due to rapid maxillary expansion.

Information

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2008
Figure 0

Table I ENT symptom severity: results of questionnaire

Figure 1

Fig. 1 (a) Lateral and (b) posteroanterior cephalometric diagrams illustrating the main measurements used. S = sella turcica; N = nasion; Po = porion; Ptm = pterygomaxillary fissure; Or = orbitale; Co = mandibular condyle; Ba = basion; PNS = posterior nasal spine; ANS = anterior nasal spine; A = subspinale; B = supramentale; Gn = gnathion; CMP = constructed mean point; RUM = right upper molar; LUM = left upper molar; RLM = right lower molar; LLM = left lower molar; Ag = right ante-gonion; Ga = left ante-gonion

Figure 2

Table II Radiological cephalometry

Figure 3

Fig. 2 Rapid maxillary expansion device and results.

Figure 4

Fig. 3 Otolaryngological infections (from questionnaire data) pre-treatment (T0) and post-treatment (T1). Whiskers indicate standard error of the mean. p < 0.001 for analysis of covariance, comparing T1 values for the two groups, corrected for the number of infections during T0. RME = rapid maxillary expansion group (n = 12); NEG = non-expanded group (n = 11); yr = year

Figure 5

Table III Post-treatment tympanography

Figure 6

Table IV Pre- and post-treatment pure tone averages*

Figure 7

Table V Change in pure tone average* with treatment

Figure 8

Table VI Speech therapy parameters